Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. more
Time Frame | PTCT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.27% | -0.4% | -1.9% |
1-Month Return | 5.98% | -4.57% | -0.37% |
3-Month Return | 23.97% | -10.14% | 4.19% |
6-Month Return | 27.37% | -5.67% | 9.34% |
1-Year Return | 59.92% | 2.53% | 25.19% |
3-Year Return | 8.84% | -0.39% | 26.48% |
5-Year Return | -7.64% | 34.57% | 85.39% |
10-Year Return | -10.49% | 103.62% | 187.16% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 306.98M | 380.77M | 538.59M | 698.80M | 937.82M | [{"date":"2019-12-31","value":32.73,"profit":true},{"date":"2020-12-31","value":40.6,"profit":true},{"date":"2021-12-31","value":57.43,"profit":true},{"date":"2022-12-31","value":74.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 12.13M | 18.94M | 32.33M | 44.68M | 65.49M | [{"date":"2019-12-31","value":18.53,"profit":true},{"date":"2020-12-31","value":28.93,"profit":true},{"date":"2021-12-31","value":49.37,"profit":true},{"date":"2022-12-31","value":68.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 294.85M | 361.82M | 506.26M | 654.12M | 872.34M | [{"date":"2019-12-31","value":33.8,"profit":true},{"date":"2020-12-31","value":41.48,"profit":true},{"date":"2021-12-31","value":58.04,"profit":true},{"date":"2022-12-31","value":74.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 96.05% | 95.03% | 94.00% | 93.61% | 93.02% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.94,"profit":true},{"date":"2021-12-31","value":97.87,"profit":true},{"date":"2022-12-31","value":97.46,"profit":true},{"date":"2023-12-31","value":96.85,"profit":true}] |
Operating Expenses | 487.64M | 759.70M | 881.21M | 1.09B | 1.31B | [{"date":"2019-12-31","value":37.17,"profit":true},{"date":"2020-12-31","value":57.91,"profit":true},{"date":"2021-12-31","value":67.17,"profit":true},{"date":"2022-12-31","value":83.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (192.80M) | (397.88M) | (374.94M) | (439.93M) | (349.40M) | [{"date":"2019-12-31","value":-19279800000,"profit":false},{"date":"2020-12-31","value":-39787500000,"profit":false},{"date":"2021-12-31","value":-37494300000,"profit":false},{"date":"2022-12-31","value":-43992500000,"profit":false},{"date":"2023-12-31","value":-34940200000,"profit":false}] |
Total Non-Operating Income/Expense | (59.62M) | (115.71M) | (229.42M) | (238.43M) | (456.11M) | [{"date":"2019-12-31","value":-5961900000,"profit":false},{"date":"2020-12-31","value":-11570900000,"profit":false},{"date":"2021-12-31","value":-22941900000,"profit":false},{"date":"2022-12-31","value":-23843300000,"profit":false},{"date":"2023-12-31","value":-45611300000,"profit":false}] |
Pre-Tax Income | (239.93M) | (402.93M) | (518.34M) | (587.49M) | (696.11M) | [{"date":"2019-12-31","value":-23992600000,"profit":false},{"date":"2020-12-31","value":-40293200000,"profit":false},{"date":"2021-12-31","value":-51834000000,"profit":false},{"date":"2022-12-31","value":-58748700000,"profit":false},{"date":"2023-12-31","value":-69611000000,"profit":false}] |
Income Taxes | 11.65M | 35.23M | 5.56M | (28.47M) | (69.51M) | [{"date":"2019-12-31","value":33.07,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":15.79,"profit":true},{"date":"2022-12-31","value":-80.82,"profit":false},{"date":"2023-12-31","value":-197.3,"profit":false}] |
Income After Taxes | (251.58M) | (438.16M) | (523.90M) | (559.02M) | (626.60M) | [{"date":"2019-12-31","value":-25157600000,"profit":false},{"date":"2020-12-31","value":-43816000000,"profit":false},{"date":"2021-12-31","value":-52390100000,"profit":false},{"date":"2022-12-31","value":-55901700000,"profit":false},{"date":"2023-12-31","value":-62660400000,"profit":false}] |
Income From Continuous Operations | (251.58M) | (438.16M) | (523.90M) | (559.02M) | (641.70M) | [{"date":"2019-12-31","value":-25157600000,"profit":false},{"date":"2020-12-31","value":-43816000000,"profit":false},{"date":"2021-12-31","value":-52390100000,"profit":false},{"date":"2022-12-31","value":-55901700000,"profit":false},{"date":"2023-12-31","value":-64170100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (251.58M) | (438.16M) | (523.90M) | (559.02M) | (626.60M) | [{"date":"2019-12-31","value":-25157600000,"profit":false},{"date":"2020-12-31","value":-43816000000,"profit":false},{"date":"2021-12-31","value":-52390100000,"profit":false},{"date":"2022-12-31","value":-55901700000,"profit":false},{"date":"2023-12-31","value":-62660400000,"profit":false}] |
EPS (Diluted) | (4.47) | (6.54) | (7.43) | (7.33) | (6.54) | [{"date":"2019-12-31","value":-447,"profit":false},{"date":"2020-12-31","value":-654,"profit":false},{"date":"2021-12-31","value":-743,"profit":false},{"date":"2022-12-31","value":-733,"profit":false},{"date":"2023-12-31","value":-654,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PTCT | |
---|---|
Cash Ratio | 1.66 |
Current Ratio | 2.10 |
Quick Ratio | 2.04 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PTCT | |
---|---|
ROA (LTM) | -5.15% |
ROE (LTM) | -7740.12% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PTCT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.57 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PTCT | |
---|---|
Trailing PE | NM |
Forward PE | 18.05 |
P/S (TTM) | 3.90 |
P/B | 1743.27 |
Price/FCF | NM |
EV/R | 3.28 |
EV/Ebitda | NM |
PEG | 0.81 |
PTC Therapeutics Inc (PTCT) share price today is $45.486
Yes, Indians can buy shares of PTC Therapeutics Inc (PTCT) on Vested. To buy PTC Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PTCT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of PTC Therapeutics Inc (PTCT) via the Vested app. You can start investing in PTC Therapeutics Inc (PTCT) with a minimum investment of $1.
You can invest in shares of PTC Therapeutics Inc (PTCT) via Vested in three simple steps:
The 52-week high price of PTC Therapeutics Inc (PTCT) is $54.16. The 52-week low price of PTC Therapeutics Inc (PTCT) is $23.58.
The price-to-earnings (P/E) ratio of PTC Therapeutics Inc (PTCT) is
The price-to-book (P/B) ratio of PTC Therapeutics Inc (PTCT) is 1743.27
The dividend yield of PTC Therapeutics Inc (PTCT) is 0.00%
The market capitalization of PTC Therapeutics Inc (PTCT) is $3.51B
The stock symbol (or ticker) of PTC Therapeutics Inc is PTCT